Podcasts · Lung Cancer Considered
FDA Approval: Zidesamtinib and ROS1 NSCLC
· 24 min
Episode FDA Approval: Zidesamtinib and ROS1 NSCLC
Patients with ROS1-positive NSCLC have a new treatment option following the FDA approval of zidesamtinib for those previously treated with a ROS1 tyrosine kinase inhibitor. In this episode, Dr. Stephen Liu, Dr. Alexander Drilon, and Dr. Rosario Charo Garcia Campelo discuss the ARROS1 trial results, the drug's efficacy and safety profile, CNS activity, and where zidesamtinib may fit into current and future treatment strategies for ROS1-positive lung cancer.
Guests:
Alexander Drilon, MD Chief, Early Drug Development Service Attending Physician, Thoracic Oncology Service Memorial Sloan Kettering Cancer Center Professor, Weill Cornell Medical College
Rosario Charo Garcia Campelo, MD Head of Medical Oncology and Thoracic Tumor Unit, Chair, University Hospital Head of the Oncology Research Group, Biomedical Research Institute A Coruna Spain
Shows are listed from Apple Podcasts' charts and directory, and Podcast Index where it is used. Every show and episode belongs to its publisher and plays from the publisher's own feed; this site hosts none of them. Explicit shows are for adult profiles only, and children’s profiles hear only children’s shows. More about this list.